SCHEMBL10396396

SCHEMBL10396396

Nc1ccc(Cl)cc1C(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.53
CCR9 P51686 1/20 0.50
P2RX1 P51575 1/20 0.48
P2RX4 Q99571 1/20 0.48
P2RX7 Q99572 1/20 0.48
TMPRSS4 Q9NRS4 1/20 0.48
CYP2C8 P10632 1/20 0.48
SRD5A2 P31213 1/20 0.47
GRIN2B Q13224 1/20 0.47
MAPT P10636 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
PTGS1 P23219 2/20 0.46
CES2 O00748 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6351799 0.85 RECQL (0.64) RECQLSRD5A2MAPTTDP1MAPK1
SCHEMBL2472942 0.83 RECQL (0.57) RECQLSRD5A2MAPTTDP1LMNA
SCHEMBL12653273 0.82 RECQL (0.60) RECQLSRD5A2MAPTTDP1MAPK1
SCHEMBL3542735 0.82 MAPT (0.67) CYP2C8SRD5A2MAPTLMNATSHR
SCHEMBL9726460 0.81 SRD5A2 (0.64) CCR9P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL19857760 0.81 CCR9 (0.49) RECQLCCR9P2RX1GRIN2BMAPT
SCHEMBL5159560 0.81 TMPRSS4 (0.55) RECQLP2RX1P2RX4P2RX7TMPRSS4
SCHEMBL6094601 0.81 MAPT (0.65) P2RX1CYP2C8SRD5A2MAPTLMNA
SCHEMBL6332774 0.81 RECQL (0.58) RECQLMAPTTDP1LMNAMAPK1
SCHEMBL31329329 0.81 MAPT (0.65) P2RX1CYP2C8SRD5A2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10577349-B2 Quinolinones as inhibitors of translation initiation complex Sanford Burnham Prebys Medical Discovery Institute (US) 2020-03-03 US disclosed
US-10577349-B2 Quinolinones as inhibitors of translation initiation complex Sanford Burnham Prebys Medical Discovery Institute (US) 2020-03-03 US disclosed
US-20180044324-A1 Quinolinones as Inhibitors of Translation Initiation Complex Sanford Burnham Prebys Medical Discovery Institute 2018-02-15 US disclosed
US-20180044324-A1 Quinolinones as Inhibitors of Translation Initiation Complex Sanford Burnham Prebys Medical Discovery Institute 2018-02-15 US disclosed
US-4898874-A Acetic acid derivatives of 3-aryl-2,1-benzisoxazole and esters and amides thereof A. H. ROBINS COMPANY, INC. (US) 1990-02-06 US disclosed
EP-0260924-A1 Antiinflammatory derivatives of 3-aryl-2,1-benzisoxazole A.H. ROBINS COMPANY, INCORPORATED (US) 1988-03-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044324-A1 Quinolinones as Inhibitors of Translation Initiation Complex EIF4E, EIF4A1, EIF4A2 RECQL 364/4885CCR9 4805/4885P2RX1 3773/4885
US-10577349-B2 Quinolinones as inhibitors of translation initiation complex EIF4E, EIF4A1, EIF4A2 RECQL 364/4885CCR9 4805/4885P2RX1 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.